Written and maintained by CASRAI Editorial Board
Last updated
This page presents biostatistical formulas, organ allocation rules, and clinical research methodology; it is not individual medical advice.
What Is the MELD Score? Definition and Clinical Purpose
The Model for End-Stage Liver Disease (MELD) score is a validated logarithmic survival model ranging from 6 to 40 that quantifies the severity of chronic liver disease and predicts 90-day mortality on the liver transplant waiting list for candidates aged 12 years and older. First validated by Malinchoc, Kamath, and colleagues at Mayo Clinic (2000–2001) using three objective laboratory values—serum total bilirubin, International Normalized Ratio (INR) of prothrombin time, and serum creatinine—the equation was expanded to MELD-Na in 2016 (adding serum sodium) and updated by the Organ Procurement and Transplantation Network (OPTN) in July 2023 to MELD 3.0 (Kim et al., 2021), which incorporates female sex, serum albumin, two physiological interaction terms, and a reduced serum creatinine ceiling of 3.0 mg/dL.
Formulas: Original MELD, MELD-Na, and OPTN MELD 3.0 With Every Symbol Explained
Across all three generations of the MELD equation, natural logarithms (ln, base e) are applied to laboratory concentrations to prevent extreme biochemical outliers from distorting linear risk predictions. Before substituting any value into the equations below, strict OPTN boundary rules must be applied.
1. Original MELD Formula — MELD(i) (Kamath et al., 2001)
MELD(i) = 9.57 × ln(Cr) + 3.78 × ln(Bili) + 11.20 × ln(INR) + 6.43- In OPTN Policy prior to MELD 3.0,
MELD(i)is rounded to the tenth decimal place before computing MELD-Na (or rounded to the nearest integer ifMELD(i) ≤ 11). - Original MELD / MELD-Na Bounds: Any value of
Bili,INR, orCrless than 1.0 is set to 1.0 (so thatln(1.0) = 0and no term becomes negative). In MELD(i) and MELD-Na,Cris capped at 4.0 mg/dL, and is automatically set to 4.0 mg/dL if the patient had ≥ 2 dialysis treatments within the prior 7 days or received 24 hours of continuous veno-venous hemodiafiltration (CVVHD) within the prior 7 days.
2. MELD-Na Formula (OPTN Policy 2016–2023)
If MELD(i) > 11, serum sodium (Na, bounded between 125 mEq/L and 137 mEq/L) is incorporated:
MELD-Na = MELD(i) + 1.32 × (137 − Na) − [ 0.033 × MELD(i) × (137 − Na) ]3. Current OPTN MELD 3.0 Formula (Kim et al., 2021; OPTN Policy 9.1.D)
Adopted by OPTN in July 2023 to remedy the systematic underestimation of renal dysfunction in women (who have lower baseline muscle mass and serum creatinine for the same glomerular filtration rate) and account for hypoalbuminemia, MELD 3.0 is calculated directly as:
MELD 3.0 = 1.33 × Female
+ 4.56 × ln(Bili)
+ 0.82 × (137 − Na)
− 0.24 × (137 − Na) × ln(Bili)
+ 9.09 × ln(INR)
+ 11.14 × ln(Cr)
+ 1.85 × (3.5 − Alb)
− 1.83 × (3.5 − Alb) × ln(Cr)
+ 6The resulting unrounded value is rounded to the nearest whole integer and bounded between a minimum score of 6 and a maximum allocation score of 40.
Symbol and Parameter Boundary Table (MELD 3.0)
| Symbol | Biochemical / Clinical Variable | Standard Units | Mandatory Pre-Calculation Floor & Ceiling (MELD 3.0) |
|---|---|---|---|
Female |
Candidate sex indicator | Binary (0 or 1) | 1 if female (adds +1.33 points); 0 if male |
Bili |
Serum total bilirubin | mg/dL | Floor = 1.0 mg/dL (values < 1.0 set to 1.0; no upper cap before final 40 cap) |
INR |
International Normalized Ratio | Dimensionless ratio | Floor = 1.0 (values < 1.0 set to 1.0) |
Cr |
Serum creatinine | mg/dL | Floor = 1.0 mg/dL; Ceiling = 3.0 mg/dL (set to 3.0 if ≥ 2 dialysis sessions or 24h CVVHD in past 7 days) |
Na |
Serum sodium concentration | mEq/L (or mmol/L) | Floor = 125 mEq/L; Ceiling = 137 mEq/L (so 137 − Na ranges from 0 to 12) |
Alb |
Serum albumin concentration | g/dL | Floor = 1.5 g/dL; Ceiling = 3.5 g/dL (so 3.5 − Alb ranges from 0.0 to 2.0) |
Worked Example With Step-by-Step Arithmetic
Consider a 54-year-old female transplant candidate (Female = 1) with decompensated cirrhosis and the following laboratory panel: Total Bilirubin = 4.0 mg/dL, INR = 1.8, Serum Creatinine = 1.9 mg/dL (no dialysis), Serum Sodium = 130 mEq/L, and Serum Albumin = 2.5 g/dL.
- Verify Bounds and Compute Natural Logarithms:
- All inputs lie inside their MELD 3.0 bounds (
Bili = 4.0 ≥ 1.0;INR = 1.8 ≥ 1.0;1.0 ≤ Cr = 1.9 ≤ 3.0;125 ≤ Na = 130 ≤ 137;1.5 ≤ Alb = 2.5 ≤ 3.5). ln(Bili) = ln(4.0) = 1.386294ln(INR) = ln(1.8) = 0.587787ln(Cr) = ln(1.9) = 0.641854137 − Na = 137 − 130 = 73.5 − Alb = 3.5 − 2.5 = 1.0
- All inputs lie inside their MELD 3.0 bounds (
- Compute Original MELD(i) and MELD-Na for Comparison:
MELD(i) = 9.57(0.641854) + 3.78(1.386294) + 11.20(0.587787) + 6.43 = 6.1425 + 5.2402 + 6.5832 + 6.43 = 24.3959 → 24.4(or integer 24).MELD-Na = 24.4 + 1.32(7) − [0.033 × 24.4 × 7] = 24.4 + 9.24 − 5.6364 = 28.0036 → 28.
- Compute MELD 3.0 Term by Term:
- Sex term:
1.33 × 1 = +1.3300 - Bilirubin main term:
4.56 × 1.386294 = +6.3215 - Sodium main term:
0.82 × 7 = +5.7400 - Bilirubin × Sodium interaction:
−0.24 × 7 × 1.386294 = −2.3290 - INR main term:
9.09 × 0.587787 = +5.3430 - Creatinine main term:
11.14 × 0.641854 = +7.1503 - Albumin main term:
1.85 × 1.0 = +1.8500 - Albumin × Creatinine interaction:
−1.83 × 1.0 × 0.641854 = −1.1746 - Intercept constant:
+6.0000
- Sex term:
- Sum and Round:
MELD 3.0 = 1.3300 + 6.3215 + 5.7400 − 2.3290 + 5.3430 + 7.1503 + 1.8500 − 1.1746 + 6.0000 = 30.2312.
Rounding to the nearest integer yields a MELD 3.0 score of 30 (gaining +2 allocation points over MELD-Na = 28 due to female sex and hypoalbuminemia adjustments).
Interpretation, Mortality Strata, and OPTN Recertification Rules
In both clinical hepatology and national organ allocation monitored by the Scientific Registry of Transplant Recipients (SRTR), higher MELD scores reflect higher 90-day waitlist mortality and mandate more frequent laboratory recertification under OPTN Policy 9.2:
| MELD Score Stratum | Estimated 3-Month Mortality (Historical Validation Cohort) | OPTN Mandatory Lab Recertification Schedule | Maximum Lab Age at Recertification |
|---|---|---|---|
| MELD ≥ 25 | ~52.6% (20–29: ~19.6%; 30–39: ~52.6%; 40: >71%) | Every 7 calendar days | Labs must be ≤ 48 hours old |
| MELD 19 – 24 | ~6.0% to 19.6% | Every 1 month (30 days) | Labs must be ≤ 7 days old |
| MELD 11 – 18 | ~6.0% | Every 3 months (90 days) | Labs must be ≤ 14 days old |
| MELD ≤ 10 | ~1.9% | Every 12 months (365 days) | Labs must be ≤ 30 days old |
In prognostic model evaluation, Kim et al. (2021) demonstrated that MELD 3.0 improved model discrimination (concordance statistic / C-index = 0.869 vs. 0.862 for MELD-Na) and prediction calibration while significantly reducing waitlist mortality disparities for female candidates and patients with small body habitus.
Assumptions and Common Mistakes
- Using the old 4.0 mg/dL creatinine cap in MELD 3.0: Original MELD and MELD-Na capped serum creatinine at 4.0 mg/dL; MELD 3.0 caps serum creatinine at 3.0 mg/dL (including for patients on dialysis). Entering 4.0 mg/dL into the MELD 3.0 equation artificially inflates the score.
- Forgetting the floor of 1.0 on logarithmic variables: If a patient has a normal bilirubin of 0.6 mg/dL or creatinine of 0.7 mg/dL,
ln(0.6)is negative (−0.511). Failing to clamp values below 1.0 to exactly 1.0 subtracts points and violates OPTN rules. - Applying MELD to pediatric patients under age 12: MELD 3.0 applies only to candidates aged 12 years and older; children under age 12 are evaluated using the Pediatric End-Stage Liver Disease (PELD) score, which incorporates age, growth failure, bilirubin, INR, and albumin (without creatinine).
- Substituting SI units (µmol/L) without conversion: All MELD equations require bilirubin and creatinine in mg/dL and albumin in g/dL. If an international clinical data registry reports bilirubin in µmol/L, divide by
17.104; if creatinine is in µmol/L, divide by88.42before applying bounds.
How to Report MELD Score (APA Style) and Integrate With EHR Workflows
When reporting MELD scores in a clinical trial manuscript or observational cohort study, always state the exact version of the equation (Original MELD, MELD-Na, or MELD 3.0) and report median and interquartile range (IQR) for skewed distributions:
“Baseline hepatic decompensation severity was quantified using the OPTN MELD 3.0 equation (Kim et al., 2021). Across the validation cohort (N = 412), median MELD 3.0 was 22 (IQR = 16–29; range = 6–40), with 38.1% (n = 157) of participants meeting the MELD 3.0 ≥ 25 high-acuity threshold.”
In hospital EHR clinical decision support workflows, automated calculators retrieve LOINC-coded HL7 FHIR Observation resources—Total Bilirubin (LOINC 1975-2), INR (LOINC 6301-6), Serum Creatinine (LOINC 2160-0), Serum Sodium (LOINC 2951-2), and Serum Albumin (LOINC 1751-7)—verify unit normalization to mg/dL, mEq/L, and g/dL, check for dialysis Procedure codes within the preceding 7 days, and compute the bounded score.
How to Calculate MELD 3.0 in R, Python, and Excel
1. R Function for MELD 3.0
calc_meld3 <- function(bili, inr, cr, na, alb, female = 0, dialysis = FALSE) {
bili_b <- pmax(bili, 1.0)
inr_b <- pmax(inr, 1.0)
cr_b <- ifelse(dialysis, 3.0, pmin(pmax(cr, 1.0), 3.0))
na_b <- pmin(pmax(na, 125.0), 137.0)
alb_b <- pmin(pmax(alb, 1.5), 3.5)
score <- 1.33 * female +
4.56 * log(bili_b) +
0.82 * (137 - na_b) -
0.24 * (137 - na_b) * log(bili_b) +
9.09 * log(inr_b) +
11.14 * log(cr_b) +
1.85 * (3.5 - alb_b) -
1.83 * (3.5 - alb_b) * log(cr_b) + 6.0
pmin(pmax(round(score), 6), 40)
}2. Python Function for MELD 3.0
import math
def calc_meld3(bili: float, inr: float, cr: float, na: float, alb: float, female: int = 0, dialysis: bool = False) -> int:
bili_b = max(bili, 1.0)
inr_b = max(inr, 1.0)
cr_b = 3.0 if dialysis else min(max(cr, 1.0), 3.0)
na_b = min(max(na, 125.0), 137.0)
alb_b = min(max(alb, 1.5), 3.5)
score = (
1.33 * (1 if female else 0)
+ 4.56 * math.log(bili_b)
+ 0.82 * (137.0 - na_b)
- 0.24 * (137.0 - na_b) * math.log(bili_b)
+ 9.09 * math.log(inr_b)
+ 11.14 * math.log(cr_b)
+ 1.85 * (3.5 - alb_b)
- 1.83 * (3.5 - alb_b) * math.log(cr_b)
+ 6.0
)
return min(max(round(score), 6), 40)3. Excel Formula for MELD 3.0
Assuming cells contain raw values in A2 (Female: 1 or 0), B2 (Bilirubin mg/dL), C2 (INR), D2 (Creatinine mg/dL, or 3 if on dialysis), E2 (Sodium mEq/L), and F2 (Albumin g/dL):
=MIN(40, MAX(6, ROUND(1.33*A2 + 4.56*LN(MAX(1,B2)) + 0.82*(137-MIN(137,MAX(125,E2))) - 0.24*(137-MIN(137,MAX(125,E2)))*LN(MAX(1,B2)) + 9.09*LN(MAX(1,C2)) + 11.14*LN(MIN(3,MAX(1,D2))) + 1.85*(3.5-MIN(3.5,MAX(1.5,F2))) - 1.83*(3.5-MIN(3.5,MAX(1.5,F2)))*LN(MIN(3,MAX(1,D2))) + 6, 0)))Frequently Asked Questions
What is meld score and how is it used in clinical research and healthcare?
The Model for End-Stage Liver Disease (MELD) score is a logarithmic mortality risk score ranging from 6 to 40 that estimates 90-day survival in patients aged 12 and older with end-stage liver disease. It is the primary metric used to prioritize deceased-donor liver transplant allocation and stratify cirrhosis severity in clinical trials.
What standards or regulatory requirements govern meld score?
In the United States, MELD calculation and recertification rules are governed by Organ Procurement and Transplantation Network (OPTN) Policy 9 under HRSA oversight. Since July 2023, OPTN uses the MELD 3.0 formula (Kim et al., 2021), which combines female sex, total bilirubin, INR, serum creatinine (capped at 3.0 mg/dL), serum sodium (125–137 mEq/L), and serum albumin (1.5–3.5 g/dL).
How does meld score integrate with EHR and health informatics workflows?
Hospital EHR systems extract LOINC-coded laboratory results (bilirubin, INR, creatinine, sodium, albumin), patient sex, and recent dialysis procedure records via HL7 FHIR APIs, apply OPTN floor and ceiling parameter bounds prior to log transformation, and track mandatory recertification deadlines (every 7 days for MELD ≥ 25).
Sources
- Kim WR, Mannalithara A, Heimbach JK, Kamath PS, Asrani SK, Biggins SW, Wood NL, Gentry SE, Kwong AJ. MELD 3.0: The Model for End-Stage Liver Disease Updated for the Modern Era. Gastroenterology. 2021;161(6):1887–1895.e4. https://pmc.ncbi.nlm.nih.gov/articles/PMC8608337/
- Kamath PS, Wiesner RH, Malinchoc M, Kremers W, Therneau TM, Kosberg CL, D’Amico G, Dickson ER, Kim WR. A model to predict survival in patients with end-stage liver disease. Hepatology. 2001;33(2):464–470. https://pubmed.ncbi.nlm.nih.gov/11172350/
- Organ Procurement and Transplantation Network (OPTN) / Health Resources and Services Administration (HRSA). OPTN Policies — Policy 9: Allocation of Livers and Liver-Intestines (MELD 3.0 Calculation and Recertification Schedule). https://optn.transplant.hrsa.gov/governance/policies/
